Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; and Sylvia L. Asa, MD, PhD, discuss challenges in the diagnosis and treatment of patients with extrapulmonary neuroendocrine carcinomas (EP-NECs), and emerging DLL3-targeted agents for patients with EP-NECs.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate key efficacy and safety data from recent and ongoing clinical trials investigating DLL3-targeted therapies and other emerging treatment strategies for EP-NECs
• Integrate biomarker testing results and emerging clinical evidence into personalized treatment plans for patients with advanced EP-NECs

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Chair:

Aman Chauhan, MD, MBBS

Associate Professor, Medicine

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Boehringer Ingelheim, Curium Group, Ipsen, Novartis, Sanofi, TerSera Therapeutics; Ownership interests in publicly traded companies: IMTX, KURA

Faculty:

Jonathan Strosberg, MD

Professor, Department of Gastrointestinal Oncology

Moffitt Cancer Center

Tampa, FL

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Boehringer Ingelheim, Curium Group, Exelixis, Merck, Sanofi; Grant/Research Funding: Exelixis, ITM, RayzeBio, Sanofi

Sylvia L. Asa, MD, PhD

Professor of Pathology

Case Western Reserve University

Pathologist

University Hospitals Cleveland

Cleveland, OH

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Boehringer Ingelheim, Leica Biosystems

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on current treatment approaches for patients with EP-NECs, go to:

https://www.gotoper.com/courses/live-tumor-board-exploring-novel-targets-and-breakthrough-treatment-strategies-in-extrapulmonary-neuroendocrine-carcinomas-c31d

Release Date

July 10, 2026

Expiration Date

July 10, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.